Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: MK-0752, Docetaxel, Pegfilgrastim
Sponsor: University of Michigan Rogel Cancer Center
Collaborators: Baylor College of Medicine|Ohio State University|Dana-Farber Cancer Institute|Weill Medical College of Cornell University|Merck Sharp & Dohme LLC